"Unique treatment potential of CBD for the prevention of relapse to drug use: preclinical proof of principle"

Cannabidiol (CBD), the major non-psychoactive constituent of Cannabis sativa, has received attention for therapeutic potential in treating neurologic and psychiatric disorders. 
Recently, CBD has also been explored for potential in treating drug addiction. 

Substance use disorders are chronically relapsing conditions and relapse risk persists for multiple reasons including craving induced by drug contexts, susceptibility to stress, elevated anxiety, and impaired impulse control. This study from NCBI was published online in 2018 Mar 22 and evaluate the “anti-relapse” potential of CBD  in animal models of drug seeking, anxiety and impulsivity.
The Study...

For the study, rats with alcohol or cocaine self-administration histories received transdermal CBD at 24 h intervals for 7 days and were tested for context and stress-induced reinstatement, as well as experimental anxiety on the elevated plus maze. 

"Study Focused on Deaths from Marijuana Compared With 17 FDA-Approved Drugs"

Much of the medical marijuana discussion has focused on the safety of marijuana compared to the safety of FDA-approved drugs. On 24 June 2005 ProCon.org sent a Freedom of Information Act (FOIA) request to the US Food and Drug Administration (FDA) to find the number of deaths caused by marijuana compared to the number of deaths caused by 17 FDA-approved drugs. 

Twelve of these FDA-approved drugs were chosen because they are commonly prescribed in place of medical marijuana, while the remaining five FDA-approved drugs were randomly selected because they are widely used and recognized by the general public. 

ProCon.org chose:

-1 January 1997 as starting date as it is the beginning of the first year following  November 1996 approval of the first state medical marijuana laws (such as California's Proposition 215). 

-The FDA reports from 13 September 2005 to 14 Octomber 2005 included drug deaths "to present", which was the date each report was compiled for our request. We cut off the counting as of 30 June 2005 to provide a uniform end-date to the various reports. 

"Hemp Oil Vs. Fish Oil"

Most of us have heard that fish oil is good for us. It contains Omega-3 fatty acids that our bodies need but can’t produce: ALA (alpha-linolenic acid), EPA (eicosa-pentaenoic acid), and DHA (docosa-hexaenoic acid). ALA is converted to EPA and DHA in the body. 

Since they cannot be produced by the body, they need to be obtained through the consumption of foods or supplements.

Omega-3 fatty acids are important because they interact with our Endocannabinoid System, the regulatory system within our bodies known to bring us back to homeostasis (a.k.a. balance). They support many bodily functions and boost immunity as well. Deficiency of Omega-3 fatty acids have been linked to multiple health issues such as heart disease, mental illness, and arthritis.

Although there is enough evidence proving that the human body may benefit from the Omegas in fish oil, there is another option:

"The Antineoplastic Activity of Cannabinoids"

Article History: This study was received on 26 December 1974, accepted on 

30 May 1975 and published on 01 September 1975  in the JNCI 

(Journal of the National Cancer Institute),Volume 55, Issue 3, Pages 597–602, https://doi.org/10.1093/jnci/55.3.597

The Summary Of The Study...

Lewis lung adenocarcrnoma growth was retarded by the oral administration of Δ9-THC, Δ8-THC, and CBN, but not CBD. 

Animals treated for 10 consecutive days with Δ9-THC, beginning the day after tumor implantation, demonstrated a dose-dependent action of retarded tumor growth. 

-Mice treated for 20 consecutive days with Δ8-THC and CBN had reduced primary tumor size. 

-CBD showed no inhibitory effect on tumor growth at 14, 21, or 28 days.

-Δ9-THC, Δ8-THC, and CBN increased the mean survival time 36% at 100 mg/kg, 25% at 200 mg/kg, and 27% at 50 mg/kg, respectively, whereas CBD did not. 

-Δ9-THC administered orally daily until death in doses of 50, 100, or 200 mg/kg did not increase the life-spans of  mice hosting the murine leukemia. 

However, Δ9-THC administered daily for 10 days significantly inhibited Friend leukemia virus-induced splenomegaly by 71% at 200 mg/kg as compared to 90.2% for actinomycin D.

Experiments with bone marrow and isolated Lewis lung cells incubated in vitro with Δ9-THC and Δ8-THC showed a dose-dependent inhibition 80–20%, respectively, of tritiated thymidine and14C-uridine uptake into these cells.

CBD was active only in high concentrations.

so.... 

As we all can understand, we dont have to do with a plant whose magical /medical benefits appeared suddenly in our lives but with a plant that is known for decades for the medical uses and in "modern life"... if you search at internet, you will find that from ancient years until today the researchers always discover something new about the benefits of Cannabis...

So the next logical thought is, who and  why they try to stay, all these studies, in the "back stage" of the knowlege...

Source: https://academic.oup.com

"Most Medical Schools Don’t Cover the ECS..."

"When will more medical schools include the second largest neurotransmitter system, the endocannabinoid system (ECS), into medical school curriculum?" article in Huffingtonpost by Dr. David Bearman

In 2013, Cardiologist Dr. David Allen did a preliminary survey to determine which schools teach the ECS and found that only a total of 13 percent of U.S. medical schools even mentioned it. Now, we’re not talking about cannabis here, but a neurotransmitter system that was discovered in the late 1980s, almost 30 years ago. We know that it is critical for homeostasis, yet few medical schools have seen fit to train medical students about it.